Table 2.
Nanocarriers utilize Transferrin receptor mediated transcytosis.
| Ligands | Nanoparticles | Cargoes | Cell lines | application |
|---|---|---|---|---|
| T7 peptide (HAIYPRH) | Liposomes | Anti-EGFR siRNA | U87 | Decrease EGFR, anti-glioma[46] |
| Transferrin, cell penetrating peptide PFVYLI (PFV) | Liposomes | doxorubicin (Dox) and Erlotinib (Erlo) | U87, brain endothelial (bEnd.3) | Anti- glioblastoma tumor [47] |
| T7 peptide | PLGA nanoparticles, magnetic nanoparticles | Paclitaxel, curcumin | U87, bEnd.3 | Anti- glioblastoma tumor [45] |
| Transferrin peptide (Tfpep) | gold nanoparticles | photodynamic pro-drug, Pc 4 | LN229, U87 | Fluorescence imaging [48] |
| Transferrin | Carbon dots | Dox | SJGBM2, CHLA266 | No in vivo data [49] |
| Transferrin, transferrin receptor monoclonal antibodies (OX26 or R17217) | Human serum albumin | Loperamide | No data | Anti-nociceptive effects [50] |
| Y-shaped ligands (with Tat peptide and transferrin) | iron oxide (Fe3O4) particles | Chlorin e6 | U87-MG | Photodynamic glioblastoma tumor therapy [51] |
| Transferrin | magnetic silica PLGA nanoparticles | Dox, paclitaxel (PTX) | U87-MG | Anti-brain glioma [52] |
| EGF peptide (YHWYGYTPQNVI), Transferrin peptide (HAIYPRH) | gold nanoparticles | photosensitizer phthalocyanine 4 (Pc 4) | LN229 | Photodynamic glioblastoma tumor therapy [53] |
| Transferrin | carbon dots | Epirubicin, temozolomide | SJGBM2, CHLA266, CHLA200 U87 | Anti- glioblastoma tumor [54] |
| D-T7 peptide | PEGylated bilirubin nanoparticles (BRNPs) | PTX, cediranib | bEnd.3, C6 cells | Antiangiogenesis and Chemotherapy of Glioma [55] |